JPH11501628A - 硫酸カルシウムを含む溶解を制御されたペレット - Google Patents
硫酸カルシウムを含む溶解を制御されたペレットInfo
- Publication number
- JPH11501628A JPH11501628A JP8526989A JP52698996A JPH11501628A JP H11501628 A JPH11501628 A JP H11501628A JP 8526989 A JP8526989 A JP 8526989A JP 52698996 A JP52698996 A JP 52698996A JP H11501628 A JPH11501628 A JP H11501628A
- Authority
- JP
- Japan
- Prior art keywords
- calcium sulfate
- sulfate hemihydrate
- pellet
- powder
- pellets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.制御可能な溶解速度を有するペレットであって、前記ペレットは硫酸カルシ ウムを含み、 (a) 実質的にα-硫酸カルシウム半水和物からなる粉末及び、任意に、実質的に β-硫酸カルシウム半水和物からなる粉末を水を含む溶液と混合して混合物を形 成し、 (b) 前記混合物をペレットに成形すること、 を含む方法により製造され、 前記の実質的にα-硫酸カルシウム半水和物からなる粉末は、98重量%硫酸カルシ ウム半水和物より高い純度、約0.4 m2/g〜約0.9 m2/gの範囲のBET表面積、約2.7 3〜約2.80 g/cm3の範囲の密度、約16μm〜約22μmの平均粒子サイズを有し、実 質的にα-硫酸カルシウム半水和物からなる粉末の90〜95重量%は約1μm〜約45μ mの粒子サイズ分布を有するものであり、 前記の実質的にβ-硫酸カルシウム半水和物からなる粉末は、98重量%硫酸カルシ ウム半水和物より高い純度、約4.5 m2/g〜約7.5 m2/gの範囲のBET表面積、約2.5 g/cm3〜約2.6 g/cm3の範囲の密度、及び約10μm〜約15μmの平均粒子サイズを 有し、 溶解速度は、実質的にβ-硫酸カルシウム半水和物からなる粉末の実質的にα-硫 酸カルシウム半水和物からなる粉末に対する重量比を0〜約3に変化させること により制御される、前記ペレット。 2.実質的にα-硫酸カルシウム半水和物からなる粉末の表面積が約0.4 m2/g〜 約0.7 m2/gの範囲にある請求項1に記載のペレット。 3.実質的にα-硫酸カルシウム半水和物からなる粉末の平均粒子サイズが約18 μm〜約22μmの範囲にある請求項1に記載のペレット。 4.実質的にβ-硫酸カルシウム半水和物からなる粉末の表面積が約5 m2/g〜約6 m2/gの範囲にある請求項1に記載のペレット。 5.実質的にβ-硫酸カルシウム半水和物からなる粉末の平均粒子サイズが約13 μm〜約14μmの範囲にある請求項1に記載のペレット。 6.実質的にβ-硫酸カルシウム半水和物からなる粉末の実質的にα-硫酸カルシ ウム半水和物からなる粉末に対する比率が0〜0.33の範囲である請求項1に記載 のペレット。 7.ペレットがさらに薬剤を含む請求項1に記載のペレット。 8.薬剤が、抗生物質、化学療法剤、増殖因子または鎮痛薬である請求項7に記 載のペレット。 9.抗生物質が、テトラサイクリン塩酸塩、バンコマイシン、トブラマイシン、 ゲンタマイシンまたはセファロスポリンである請求項8に記載のペレット。 10.化学療法剤がシスプラチナム、イホスファミド、メトトレキセートまたはド キソルビシン塩酸塩である請求項8に記載のペレット。 11.増殖因子が、トランスフォーミング増殖因子β、骨形成タンパク質、塩基性 線維芽細胞増殖因子、血小板由来増殖因子またはその他のポリペプチド増殖因子 である請求項8に記載のペレット。 12.鎮痛薬が、リドカイン塩酸塩、ビピバカイン塩酸塩またはケトロラックトロ メタミンである請求項8に記載のペレット。 13.溶液がさらに塩化ナトリウムを含む請求項1に記載のペレット。 14.水のα-硫酸カルシウム半水和物及びβ-硫酸カルシウム半水和物に対する重 量比が約0.22〜約1の範囲である請求項1に記載のペレット。 15.水のα-硫酸カルシウム半水和物及びβ-硫酸カルシウム半水和物に対する重 量比が約0.27〜約0.30の範囲である請求項14に記載のペレット。 16.請求項1(a)の混合物に圧力にかけることを含む、制御可能な溶解速度を有す るペレットの製造方法。 17.請求項1(a)の混合物を型成形することを含む、制御可能な溶解速度を有する ペレットの製造方法。 18.ペレットがさらに薬剤を含む請求項6に記載のペレット。 19.薬剤が、抗生物質、化学療法剤、増殖因子または鎮痛薬である請求項18に記 載のペレット。 20.抗生物質が、テトラサイクリン塩酸塩、バンコマイシン、トブラマイシン、 ゲンタマイシンまたはセファロスポリンである請求項19に記載のペレット。 21.化学療法剤がシスプラチナム、イホスファミド、メトトレキセートまたはド キソルビシン塩酸塩である請求項19に記載のペレット。 22.鎮痛薬が、リドカイン塩酸塩、ビピバカイン塩酸塩またはケトロラックトロ メタミンである請求項19に記載のペレット。 23.硫酸カルシウム及び薬剤を含むペレットを、ヒトまたは動物に移植すること を含む、薬剤をin vivo でデリバリーする方法であって、前記ペレットが、 (a) 実質的にα-硫酸カルシウム半水和物からなる粉末、薬剤、水を含む溶液及 び、任意に、実質的にβ-硫酸カルシウム半水和物からなる粉末を混合し、 (b) 前記混合物をペレットに成形すること、 を含む方法により製造され、 前記の実質的にα-硫酸カルシウム半水和物からなる粉末は、98重量%硫酸カルシ ウム半水和物より高い純度、約0.4 m2/g〜約0.9 m2/gの範囲のBET表面積、約2.7 3〜約2.80 g/cm3の範囲の密度、約16μm〜約22μmの平均粒子サイズを有し、実 質的にα-硫酸カルシウム半水和物からなる粉末の90〜95重量%は約1μm〜約45μ mの粒子サイズ分布を有するものであり、 前記の実質的にβ-硫酸カルシウム半水和物からなる粉末は、98重量%硫酸カルシ ウム半水和物より高い純度、約4.5 m2/g〜約7.5 m2/gの範囲のBET表面積、約2.5 g/cm3〜約2.6 g/cm3の範囲の密度、及び約10μm〜約15μmの範囲の平均粒子サ イズを有し、 溶解速度は、実質的にβ-硫酸カルシウム半水和物からなる粉末の実質的にα-硫 酸カルシウム半水和物からなる粉末に対する重量比を0〜約3に変化させること により制御される、前記方法。 24.薬剤が、抗生物質、化学療法剤、増殖因子または鎮痛薬である請求項23に記 載の方法。 25.抗生物質が、テトラサイクリン塩酸塩、バンコマイシン、トブラマイシン、 ゲンタマイシンまたはセファロスポリンである請求項24に記載の方法。 26.化学療法剤がシスプラチナム、イホスファミド、メトトレキセートまたはド キソルビシン塩酸塩である請求項24に記載の方法。 27.増殖因子が、トランスフォーミング増殖因子β、骨形成タンパク質、塩基性 線維芽細胞増殖因子、血小板由来増殖因子またはその他のポリペプチド増殖因子 である請求項24に記載の方法。 28.鎮痛薬が、リドカイン塩酸塩、ビピバカイン塩酸塩またはケトロラックトロ メタミンである請求項24に記載の方法。 29.溶液が塩化ナトリウムも含む請求項23に記載の方法。 30.水のα-硫酸カルシウム半水和物及びβ-硫酸カルシウム半水和物に対する重 量比が約0.22〜約1の範囲である請求項23に記載の方法。 31.水のα-硫酸カルシウム半水和物及びβ-硫酸カルシウム半水和物に対する重 量比が約0.27〜約0.30の範囲である請求項30に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/399,769 | 1995-03-07 | ||
US08/399,769 US5614206A (en) | 1995-03-07 | 1995-03-07 | Controlled dissolution pellet containing calcium sulfate |
PCT/US1996/002930 WO1996027346A1 (en) | 1995-03-07 | 1996-03-04 | Controlled dissolution pellet containing calcium sulfate |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11501628A true JPH11501628A (ja) | 1999-02-09 |
JP4294091B2 JP4294091B2 (ja) | 2009-07-08 |
Family
ID=23580887
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52698996A Expired - Lifetime JP4294091B2 (ja) | 1995-03-07 | 1996-03-04 | 硫酸カルシウムを含む溶解を制御されたペレット |
Country Status (8)
Country | Link |
---|---|
US (3) | US5614206A (ja) |
EP (1) | EP0813396A4 (ja) |
JP (1) | JP4294091B2 (ja) |
KR (1) | KR19980702798A (ja) |
AU (1) | AU701508B2 (ja) |
CA (1) | CA2214788C (ja) |
IL (1) | IL117363A (ja) |
WO (1) | WO1996027346A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009529554A (ja) * | 2006-03-14 | 2009-08-20 | リッズ エービー | 生体吸収性の制御放出組成物 |
JP2013067639A (ja) * | 2005-03-31 | 2013-04-18 | Lidds Ab | 活性物質の局所送達に基づく前立腺疾患の治療方法 |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
DE19620117C1 (de) * | 1996-05-18 | 1997-07-24 | Corimed Kundenorientierte Medi | Verfahren zur Herstellung eines calciumsulfathaltigen medizinischen Präparats und calciumsulfathaltiges medizinisches Präparat |
FR2759293B1 (fr) | 1997-02-11 | 1999-04-30 | Ethypharm Lab Prod Ethiques | Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie |
US6391336B1 (en) * | 1997-09-22 | 2002-05-21 | Royer Biomedical, Inc. | Inorganic-polymer complexes for the controlled release of compounds including medicinals |
BR9814615A (pt) | 1997-10-22 | 2001-10-16 | Jens Ponikau | Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa |
US7147666B1 (en) | 1997-11-26 | 2006-12-12 | Bernard Francis Grisoni | Monolithic implants with openings |
US6251418B1 (en) * | 1997-12-18 | 2001-06-26 | C.R. Bard, Inc. | Systems and methods for local delivery of an agent |
US6197324B1 (en) * | 1997-12-18 | 2001-03-06 | C. R. Bard, Inc. | System and methods for local delivery of an agent |
DE69943218D1 (de) * | 1998-09-01 | 2011-04-07 | Nippon Soda Co | Schlammentferner und substanz zum verhindern/entfernen von schlamm |
US6689121B1 (en) | 1998-09-24 | 2004-02-10 | C. R. Bard, Inc. | Systems and methods for treating ischemia |
US6432126B1 (en) | 1998-09-30 | 2002-08-13 | C.R. Bard, Inc. | Flexible vascular inducing implants |
US6251079B1 (en) | 1998-09-30 | 2001-06-26 | C. R. Bard, Inc. | Transthoracic drug delivery device |
US6248112B1 (en) | 1998-09-30 | 2001-06-19 | C. R. Bard, Inc. | Implant delivery system |
US6458092B1 (en) | 1998-09-30 | 2002-10-01 | C. R. Bard, Inc. | Vascular inducing implants |
US6224635B1 (en) * | 1998-11-06 | 2001-05-01 | Hospital For Joint Diseases | Implantation of surgical implants with calcium sulfate |
US6692520B1 (en) | 1998-12-15 | 2004-02-17 | C. R. Bard, Inc. | Systems and methods for imbedded intramuscular implants |
AU760593B2 (en) * | 1999-02-02 | 2003-05-15 | Wright Medical Technology, Inc. | Controlled release composite |
JP2002539172A (ja) | 1999-03-17 | 2002-11-19 | ノバルティス アクチエンゲゼルシャフト | Tgf−ベータを含む医薬組成物 |
US6986784B1 (en) | 1999-05-14 | 2006-01-17 | C. R. Bard, Inc. | Implant anchor systems |
US7371408B1 (en) * | 1999-06-07 | 2008-05-13 | Wright Medical Technology, Inc. | Bone graft substitute composition |
US6855160B1 (en) | 1999-08-04 | 2005-02-15 | C. R. Bard, Inc. | Implant and agent delivery device |
DE19953771C1 (de) * | 1999-11-09 | 2001-06-13 | Coripharm Medizinprodukte Gmbh | Resorbierbares Knochen-Implantatmaterial sowie Verfahren zur Herstellung desselben |
DE19960504A1 (de) * | 1999-12-15 | 2001-08-16 | Curasan Ag | Regenerationsmittel |
DE19960490A1 (de) * | 1999-12-15 | 2001-07-12 | Curasan Ag | Regenerationsmittel |
CN1426290A (zh) * | 2000-03-03 | 2003-06-25 | 史密夫和内修有限公司 | 用于骨缺陷的定形颗粒和组合物以及该颗粒的制作方法 |
US6630153B2 (en) * | 2001-02-23 | 2003-10-07 | Smith & Nephew, Inc. | Manufacture of bone graft substitutes |
SE520688C2 (sv) | 2000-04-11 | 2003-08-12 | Bone Support Ab | Ett injicerbart ersättningsmaterial för benmineral |
US6387172B1 (en) | 2000-04-25 | 2002-05-14 | United States Gypsum Company | Gypsum compositions and related methods |
US7232421B1 (en) | 2000-05-12 | 2007-06-19 | C. R. Bard, Inc. | Agent delivery systems |
SE517168C2 (sv) * | 2000-07-17 | 2002-04-23 | Bone Support Ab | En komposition för ett injicerbart ersättningsmaterial för benmineral |
US7204847B1 (en) | 2000-07-28 | 2007-04-17 | C. R. Bard, Inc. | Implant anchor systems |
US6497901B1 (en) | 2000-11-02 | 2002-12-24 | Royer Biomedical, Inc. | Resorbable matrices for delivery of bioactive compounds |
DE10114244A1 (de) * | 2001-03-22 | 2002-10-02 | Heraeus Kulzer Gmbh & Co Kg | Antibiotikum-/Antibiotika-Zubereitung mit retardierender Wirkstofffreisetzung |
DE10114245A1 (de) * | 2001-03-22 | 2002-10-02 | Heraeus Kulzer Gmbh & Co Kg | Herstellung und Verwendung einer Antibiotikum-/Antibiotika-Zubereitung |
DE10114364A1 (de) * | 2001-03-22 | 2002-10-02 | Heraeus Kulzer Gmbh & Co Kg | Verfahren zur Herstellung von antibiotischen Kompositen |
US20020169066A1 (en) * | 2001-04-16 | 2002-11-14 | Cerabio, L.L.C. | Dense porous structures for use as bone substitutes |
WO2003015800A1 (en) * | 2001-08-09 | 2003-02-27 | Ivoclar Vivadent, Inc. | Tissue implants and methods for making and using same |
US7371409B2 (en) | 2001-09-06 | 2008-05-13 | Wright Medical Technology, Inc. | Bone graft substitute composition |
US6822033B2 (en) | 2001-11-19 | 2004-11-23 | United States Gypsum Company | Compositions and methods for treating set gypsum |
SE522098C2 (sv) * | 2001-12-20 | 2004-01-13 | Bone Support Ab | Ett nytt benmineralsubstitut |
EP1489998B1 (en) * | 2002-03-29 | 2010-12-08 | Wright Medical Technology, Inc. | Bone graft substitute composition |
US7159272B2 (en) * | 2002-05-14 | 2007-01-09 | Emerson Electric Co. | Detachable accessory holder |
US7291179B2 (en) | 2002-06-24 | 2007-11-06 | Wright Medical Technology, Inc. | Bone graft substitute composition |
US6652887B1 (en) | 2002-06-24 | 2003-11-25 | Wright Medical Technology, Inc. | Bone graft substitute composition |
US20040109893A1 (en) * | 2002-06-25 | 2004-06-10 | Guohua Chen | Sustained release dosage forms of anesthetics for pain management |
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
US7507257B2 (en) * | 2003-02-04 | 2009-03-24 | Wright Medical Technology, Inc. | Injectable resorbable bone graft material, powder for forming same and methods relating thereto for treating bone defects |
SE0300620D0 (sv) * | 2003-03-05 | 2003-03-05 | Bone Support Ab | A new bone substitute composition |
WO2004098457A1 (en) * | 2003-04-30 | 2004-11-18 | Therics, Inc. | Bone void filler and method of manufacture |
FR2856594B1 (fr) * | 2003-06-26 | 2006-03-03 | Oreal | Particules poreuses chargees en compose(s) actif(s) cosmetique(s) ou pharmaceutique(s) |
US20050031699A1 (en) * | 2003-06-26 | 2005-02-10 | L'oreal | Porous particles loaded with cosmetically or pharmaceutically active compounds |
EP1680089B1 (en) | 2003-10-22 | 2013-09-11 | Lidds AB | Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
US20050098915A1 (en) * | 2003-11-07 | 2005-05-12 | Smith & Nephew Inc. | Manufacture of bone graft substitutes |
SE0302983D0 (sv) * | 2003-11-11 | 2003-11-11 | Bone Support Ab | Anordning för att förse spongiöst ben med benersättnings- och/eller benförstärkningsmaterial och förfarande i samband därmed |
SE527528C2 (sv) | 2004-06-22 | 2006-04-04 | Bone Support Ab | Anordning för framställning av härdbar massa samt användning av anordningen |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
US7250550B2 (en) * | 2004-10-22 | 2007-07-31 | Wright Medical Technology, Inc. | Synthetic bone substitute material |
US20060093646A1 (en) * | 2004-10-28 | 2006-05-04 | Cima Michael J | Orthopedic and dental implant devices providing controlled drug delivery |
DE102004060666B3 (de) * | 2004-12-15 | 2006-03-30 | Heraeus Kulzer Gmbh | Antibiotikum/Antibiotika enthaltendes Knochenersatzmaterial mit retardierender Wirkstofffreisetzung |
US8221504B2 (en) | 2005-02-23 | 2012-07-17 | Wright Medical Technology, Inc. | Coating an implant for increased bone in-growth |
US20060233849A1 (en) * | 2005-04-13 | 2006-10-19 | Simon Bruce J | Composite bone graft material |
US7621963B2 (en) * | 2005-04-13 | 2009-11-24 | Ebi, Llc | Composite bone graft material |
WO2007001624A2 (en) * | 2005-06-28 | 2007-01-04 | Microchips, Inc. | Medical and dental implant devices for controlled drug delivery |
AU2006287478B2 (en) | 2005-09-09 | 2012-02-02 | Agnovos Healthcare, Llc | Composite bone graft substitute cement and articles produced therefrom |
US8025903B2 (en) * | 2005-09-09 | 2011-09-27 | Wright Medical Technology, Inc. | Composite bone graft substitute cement and articles produced therefrom |
CN101370531A (zh) * | 2005-11-17 | 2009-02-18 | 生物模拟治疗公司 | 采用rhPDGF-BB和生物相容性基质的颌面骨增高 |
CN100581594C (zh) * | 2006-01-17 | 2010-01-20 | 叶南辉 | 具有混凝土特性的生物骨材的制造方法 |
EP1991282B1 (en) * | 2006-02-09 | 2013-06-19 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
US20080063681A1 (en) * | 2006-09-11 | 2008-03-13 | Ebi, L.P. | Therapeutic bone replacement material |
US20080081060A1 (en) * | 2006-10-03 | 2008-04-03 | Haggard Warren O | Chitosan-coated calcium sulfate based medicament delivery system |
EP2086598B1 (en) * | 2006-11-03 | 2015-05-27 | BioMimetic Therapeutics, LLC | Compositions and methods for arthrodetic procedures |
WO2008094585A1 (en) * | 2007-01-30 | 2008-08-07 | The Research Foundation Of State University Of New York | Calcium sulfate based nanoparticles |
US8070895B2 (en) | 2007-02-12 | 2011-12-06 | United States Gypsum Company | Water resistant cementitious article and method for preparing same |
AU2008218763B2 (en) * | 2007-02-20 | 2013-10-24 | Biomimetic Therapeutics, Llc. | Prevention and treatment for osteonecrosis and osteoradionecrosis of the jaw using PDGF and a bone matrix |
CN102688492A (zh) * | 2007-03-23 | 2012-09-26 | 分子研究中心公司 | 包含四环素类的抗炎组合物及其用途 |
US20110236501A1 (en) * | 2007-09-05 | 2011-09-29 | Vanderbilt University | Injectable dual delivery allograph bone/polymer composite for treatment of open fractures |
ES2422259T3 (es) | 2008-02-07 | 2013-09-10 | Biomimetic Therapeutics Inc | Composiciones para la osteogénesis por distracción |
EP2163532A1 (de) * | 2008-09-11 | 2010-03-17 | Claudius Peters Technologies GmbH | Verfahren und Anlage zur Herstellung von Hartgips |
US20100125303A1 (en) * | 2008-11-20 | 2010-05-20 | Daley Robert J | Methods and apparatus for replacing biological joints using bone mineral substance in a suspended state |
US20100125335A1 (en) * | 2008-11-20 | 2010-05-20 | Daley Robert J | Methods and apparatus for replacing biological joints using bone cement in a suspended state |
US8906817B2 (en) | 2009-01-12 | 2014-12-09 | National Taiwan University | Sintered calcium sulfate ceramic material and sinterable calcium sulfate ceramic material |
AU2010221089A1 (en) * | 2009-03-05 | 2011-09-15 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects |
US8329308B2 (en) | 2009-03-31 | 2012-12-11 | United States Gypsum Company | Cementitious article and method for preparing the same |
TWI468366B (zh) * | 2009-09-30 | 2015-01-11 | Yu Hsueh Lin | 無水硫酸鈣生醫材料之燒結方法 |
WO2011082258A2 (en) * | 2009-12-30 | 2011-07-07 | Regents Of The University Of Minnesota | Bone cement and method |
BR112012017535A2 (pt) | 2010-01-15 | 2019-09-24 | Of Medicine And Dentistry Of New Jersey University | uso de compostos de vanádio para cicatrização de osso |
US9180137B2 (en) | 2010-02-09 | 2015-11-10 | Bone Support Ab | Preparation of bone cement compositions |
US20140322292A1 (en) | 2010-12-10 | 2014-10-30 | Rutgers, The State University Of New Jersey | Insulin-mimetics as therapeutic adjuncts for bone regeneration |
US20170035803A1 (en) * | 2010-12-10 | 2017-02-09 | Rutgers, The State University Of New Jersey | Insulin-mimetic local therapeutic adjuncts for enhancing spinal fusion |
DE102010055561B4 (de) | 2010-12-23 | 2015-12-31 | Heraeus Medical Gmbh | Beschichtungsverfahren und Beschichtungsvorrichtung |
US8586074B2 (en) * | 2011-02-08 | 2013-11-19 | Orthogen, Llc | Calcium sulfate composite particles including aggregated calcium sulfate nanoparticles and method of use for bone augmentation |
US9931348B2 (en) | 2011-07-06 | 2018-04-03 | Rutgers, The State University Of New Jersey | Vanadium compounds as therapeutic adjuncts for cartilage injury and repair |
AU2013334111A1 (en) * | 2012-10-25 | 2015-05-28 | Rutgers, The State University Of New Jersey | Insulin-mimetic local therapeutic adjuncts for enhancing spinal fusion |
ES2671122T3 (es) | 2013-02-20 | 2018-06-05 | Bone Support Ab | Endurecimiento mejorado de sustituto óseo endurecible |
TWI651103B (zh) | 2013-12-13 | 2019-02-21 | 萊特醫技股份有限公司 | 多相骨移植替代材料 |
US9839718B1 (en) | 2014-01-10 | 2017-12-12 | University Of South Florida | Intracorporal ultra high purity calcium sulfate cast mixed with antimicrobials for the treatment of penile implant infections |
US9895354B2 (en) | 2014-04-04 | 2018-02-20 | University Of Kentucky Research Foundation | Bilayered calcium sulfate/calcium phosphate space-making composites with multiple drug delivery capabilities |
PL3331826T3 (pl) * | 2016-10-17 | 2019-08-30 | Lidds Ab | Nowy sposób wytwarzania półwodzianu siarczanu wapnia o unikalnych właściwościach |
CA3167217A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
GB202108727D0 (en) * | 2021-06-18 | 2021-08-04 | Biocomposites Ltd | Composition comprising calcium sulfate with vancomycin and gentamicin |
GB202108729D0 (en) * | 2021-06-18 | 2021-08-04 | Biocomposites Ltd | Composition comprising calcium sulfate with vancomycin and tobramycin |
EP4382109A1 (de) | 2022-12-06 | 2024-06-12 | Heraeus Medical GmbH | Anwendung eines kompositmaterials |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3279998A (en) * | 1962-06-22 | 1966-10-18 | Smith Kline French Lab | Method of preparing sustained release tablets |
US3632739A (en) * | 1969-12-29 | 1972-01-04 | Sandoz Ag | Solid sustained release pharmaceutical preparation |
US4619653A (en) * | 1979-04-27 | 1986-10-28 | The Johns Hopkins University | Apparatus for detecting at least one predetermined condition and providing an informational signal in response thereto in a medication infusion system |
DK313381A (da) * | 1980-07-24 | 1982-01-25 | Mckechnike Chemicals Ltd | Reguleret frigoerelse af sporstoffer |
US4519801A (en) * | 1982-07-12 | 1985-05-28 | Alza Corporation | Osmotic device with wall comprising cellulose ether and permeability enhancer |
US4732762A (en) * | 1983-03-07 | 1988-03-22 | Metropolitan Mosquito Control District | Timed release pest control composition and means |
US4619655A (en) * | 1984-01-26 | 1986-10-28 | University Of North Carolina | Plaster of Paris as a bioresorbable scaffold in implants for bone repair |
NL8401062A (nl) * | 1984-04-04 | 1985-11-01 | Stichting Biomaterials Science | Werkwijze voor het bereiden van een implantatiemateriaal dat geneesmiddelen afgeeft in het lichaam. |
JPS61293911A (ja) * | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | 徐放化製剤 |
DE3542972A1 (de) * | 1985-12-05 | 1987-06-11 | Merck Patent Gmbh | Pharmakadepot |
US4900546A (en) * | 1987-07-30 | 1990-02-13 | Pfizer Hospital Products Group, Inc. | Bone cement for sustained release of substances |
US5147403A (en) * | 1989-03-15 | 1992-09-15 | United States Gypsum Company | Prosthesis implantation method |
US5149368A (en) * | 1991-01-10 | 1992-09-22 | Liu Sung Tsuen | Resorbable bioactive calcium phosphate cement |
US5262166A (en) * | 1991-04-17 | 1993-11-16 | Lty Medical Inc | Resorbable bioactive phosphate containing cements |
US5281265A (en) * | 1992-02-03 | 1994-01-25 | Liu Sung Tsuen | Resorbable surgical cements |
US5290572A (en) * | 1992-08-06 | 1994-03-01 | Deo Corporation | Opthalmic composition for treating dry eye |
NO940913L (no) * | 1993-03-26 | 1994-09-27 | Bristol Myers Squibb Co | Preparater for kontrollert frigivelse av biologisk aktiv TGF- |
US5614206A (en) * | 1995-03-07 | 1997-03-25 | Wright Medical Technology, Inc. | Controlled dissolution pellet containing calcium sulfate |
-
1995
- 1995-03-07 US US08/399,769 patent/US5614206A/en not_active Expired - Lifetime
-
1996
- 1996-03-04 IL IL11736396A patent/IL117363A/xx not_active IP Right Cessation
- 1996-03-04 EP EP96907921A patent/EP0813396A4/en not_active Withdrawn
- 1996-03-04 AU AU51355/96A patent/AU701508B2/en not_active Expired
- 1996-03-04 CA CA002214788A patent/CA2214788C/en not_active Expired - Lifetime
- 1996-03-04 WO PCT/US1996/002930 patent/WO1996027346A1/en not_active Application Discontinuation
- 1996-03-04 KR KR1019970706205A patent/KR19980702798A/ko not_active Application Discontinuation
- 1996-03-04 JP JP52698996A patent/JP4294091B2/ja not_active Expired - Lifetime
- 1996-12-11 US US08/763,021 patent/US5807567A/en not_active Expired - Lifetime
-
1998
- 1998-09-02 US US09/145,671 patent/US6030636A/en not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013067639A (ja) * | 2005-03-31 | 2013-04-18 | Lidds Ab | 活性物質の局所送達に基づく前立腺疾患の治療方法 |
JP2009529554A (ja) * | 2006-03-14 | 2009-08-20 | リッズ エービー | 生体吸収性の制御放出組成物 |
Also Published As
Publication number | Publication date |
---|---|
US6030636A (en) | 2000-02-29 |
CA2214788C (en) | 2006-12-05 |
WO1996027346A1 (en) | 1996-09-12 |
KR19980702798A (ko) | 1998-08-05 |
AU5135596A (en) | 1996-09-23 |
IL117363A0 (en) | 1996-07-23 |
JP4294091B2 (ja) | 2009-07-08 |
AU701508B2 (en) | 1999-01-28 |
CA2214788A1 (en) | 1996-09-12 |
EP0813396A1 (en) | 1997-12-29 |
US5807567A (en) | 1998-09-15 |
MX9706809A (es) | 1997-11-29 |
IL117363A (en) | 2000-09-28 |
EP0813396A4 (en) | 2000-04-19 |
US5614206A (en) | 1997-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11501628A (ja) | 硫酸カルシウムを含む溶解を制御されたペレット | |
EP1152709B1 (en) | Controlled release composite | |
Yu et al. | Self‐setting hydroxyapatite cement: A novel skeletal drug‐delivery system for antibiotics | |
CA2745934C (en) | Sustained release systems of ascorbic acid phosphate | |
Otsuka et al. | A novel skeletal drug delivery system using a self‐setting calcium phosphate cement. 5. Drug release behavior from a heterogeneous drug‐loaded cement containing an anticancer drug | |
EP1933892B1 (en) | Composite bone graft substitute cement and articles produced therefrom | |
EP1962716A2 (en) | Porous calcium phosphate bone material | |
AU2018204187B2 (en) | Multiphasic bone graft substitute material | |
CN85105953A (zh) | 活性化合物的储存物 | |
JP3170059B2 (ja) | リン酸カルシウム系薬物徐放体及びその製造方法 | |
Lasserre et al. | Ceramic drug-delivery devices | |
TWI667046B (zh) | 用於形成三維支架的生物可再吸收陶瓷組成物 | |
Di Silvio et al. | Validation and optimization of a polymer system for potential use as a controlled drug-delivery system | |
WO2002041844A9 (en) | Chemotherapeutic composition using nanocrystalline calcium phosphate paste | |
WO2002065981A2 (en) | Chemotherapeutic composition using calcium phosphate paste | |
JP5307025B2 (ja) | ポリマー・マトリックスを有する生成物を生成する方法、その生成物からなるインプラント、およびそれらの使用 | |
MXPA97006809A (en) | Controlled dissolution pella cal contienesulfato | |
JPH04506471A (ja) | 生物分解可能の移植可能の材料及びその製造方法 | |
OTSUKA et al. | New skeletal drug delivery system containing antibiotics using self-setting bioactive glass cement | |
WO2004071547A1 (en) | Bone filling material comprising anabolic steroid | |
Krausher | Investigating calcium polyphosphate addition to a conventional calcium phosphate cement for bone-interfacing applications. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061017 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070226 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070417 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090317 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090408 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120417 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120417 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130417 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130417 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140417 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |